GLP-1s and Gastroparesis: What “Stomach Paralysis” Means

“Stomach paralysis” is an alarming phrase often used for gastroparesis. GLP-1 medicines slow gastric emptying, but an expected pharmacologic effect, ordinary nausea, and a diagnosed stomach-emptying disorder are not interchangeable.

Persistent or severe symptoms deserve assessment. At the same time, seeing a headline about gastroparesis does not tell you your personal likelihood of developing it, whether your symptoms have that cause, or how long they will last.

What gastroparesis means

Gastroparesis involves delayed movement of food out of the stomach without a mechanical blockage. Symptoms can include feeling full soon after starting a meal, prolonged fullness, nausea, and vomiting. Diabetes and other conditions can cause gastroparesis, and some medications can produce similar symptoms.¹

Symptoms alone cannot reliably separate those possibilities. A clinician may need to review your medicines, exclude an obstruction or another illness, and assess stomach emptying. Do not interpret a bad day of nausea as a confirmed diagnosis—or assume repeated vomiting is harmless because nausea appears on a drug label.

Our Zepbound side-effect guide separates common treatment symptoms from situations needing prompt contact. A diagnosis requires more than matching an internet symptom list.

What approved labeling says

Zepbound delays gastric emptying and is not recommended in patients with severe gastroparesis. Its labeling also warns about severe gastrointestinal adverse reactions.² Wegovy has corresponding gastrointestinal precautions and is not recommended for patients with severe gastroparesis.³

These warnings matter when a clinician assesses your history before prescribing. They do not establish that everyone with temporary nausea has gastroparesis, or that every diagnosed case is permanent. Nor do they provide an individual risk estimate for someone using a different compounded formulation.

The labeling describes different outcomes separately. Rates for all gastrointestinal reactions or severe gastrointestinal reactions must not be relabeled as rates of confirmed gastroparesis.

The frequently quoted observational study

A 2023 JAMA research letter analyzed insurance claims among people identified as using GLP-1 medicines for weight loss. It compared semaglutide and liraglutide with bupropion-naltrexone. The reported gastroparesis incidence was:⁴

9.1 per 1,000 person-years is not 9.1%. Person-years combine the number of people with their follow-up time; this rate is roughly nine events per 1,000 people followed for one year under comparable study conditions. It is not a lifetime risk prediction.

The combined GLP-1 comparison had an adjusted hazard ratio of 3.67, with a wide 95% confidence interval of 1.15 to 11.90. That is an association with substantial uncertainty, particularly with only four semaglutide events and three comparator events.

What those numbers cannot establish

This was not a randomized trial. Claims-based definitions, differences between treatment groups, unmeasured factors, and uncertainty about the actual treatment indication can influence results. The data came from an earlier prescribing period and did not evaluate modern tirzepatide treatment as a separate group.⁴

Consequently, the table should not be used to rank today's individual providers or predict your chance of permanent injury. It also cannot establish the outcome of a legal claim. A reported association is a reason for clinical attention and further study, not a substitute for evaluating a particular patient's symptoms.

Symptoms that should change the conversation

Tell your clinician about persistent vomiting, feeling full after very little food, an inability to maintain nutrition, or symptoms that continue or worsen. Seek urgent assessment when severe pain, inability to keep fluids down, or other serious symptoms make waiting unsafe. Dehydration and other illnesses can require care even without a gastroparesis diagnosis.

Our pancreatitis and gallbladder article covers other reasons abdominal symptoms should be assessed. The point is to avoid choosing a diagnosis yourself from overlapping symptoms.

Before any procedure requiring anesthesia or deep sedation, tell the procedural team about your GLP-1 medicine. Delayed emptying is relevant to aspiration precautions, but the team should give individualized instructions; this article does not provide a universal pre-procedure stopping schedule.²³

Arrange care before there is a problem

Ask a prospective provider how to reach a clinician, what happens when symptoms develop between renewals, and where urgent care should occur. Our provider checklist makes response access part of choosing a service.

If treatment must be interrupted, discuss follow-up and restarting rather than independently changing the regimen. The stopping-treatment guide explains longer-term planning without turning trial averages into an instruction to continue despite concerning symptoms.

Persistent symptoms need assessment in context. Read constipation during tirzepatide treatment and sulfur burps during semaglutide treatment for symptom-specific evidence and limits. Before anesthesia or deep sedation, use our GLP-1 procedure guide to prepare questions for the prescribing and anesthesia teams; do not choose a medication-hold schedule from an article.